This presentation contains "forward-looking" statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These uncertainties may cause our actual future results to be materially different than those expressed in our forward looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are available on the “Financial Information” section of our website at www.perkinelmer.com.
OUR MISSION

Innovating for a healthier world
OUR TRANSFORMATION
<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2014</th>
<th>Today</th>
</tr>
</thead>
<tbody>
<tr>
<td>Life Sciences</td>
<td>26%</td>
<td>45%</td>
<td>Diversified by</td>
</tr>
<tr>
<td>Diagnostics</td>
<td>22%</td>
<td></td>
<td>Medical Imaging</td>
</tr>
<tr>
<td>Medical Imaging</td>
<td>7%</td>
<td></td>
<td>Food Testing</td>
</tr>
<tr>
<td>Consumables, Services, Software</td>
<td>55%</td>
<td>45%</td>
<td>Diversified Portfolio</td>
</tr>
<tr>
<td>Instruments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emerging Markets</td>
<td>28%</td>
<td></td>
<td>Doubled</td>
</tr>
<tr>
<td>Developed Markets</td>
<td>72%</td>
<td></td>
<td>Diagnostics Revenue</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Strategic Focus**
- **Attractive END MARKETS**
- **Improved PRODUCT MIX**
- **Increased GEOGRAPHIC REACH**
- **Strengthened CAPABILITIES**
- **Basic research-focus in Life Sciences**
- **Diagnostics strength primarily in Newborn Screening**
- **Episodic, unfocused approach in Food**

**Today**
- **Doubled**
- **Diversified by Medical Imaging**
- **Food Testing**
- **Doubled Portfolio**
- **Increased our Emerging Market presence to over 40%**
- **Tripled**
- **Total Addressable Market to ~$50B**
- **Significant organic and inorganic capabilities expansion including 18 acquisitions**

Note: % represent percent of total PerkinElmer revenue
PERKINELMER TODAY

Diagnostics

$2.9B
2019E revenue*

Diagnostics & Discovery & Analytical Solutions

70%
Consumables, Services, Software

30%
Instruments

38%
AMERICAS

28%
EUROPE

34%
ASIA PACIFIC

7%
CAGR (’14-’19)

11%
CAGR (’14-’19)

Select portfolio additions:

* Estimate is based on guidance provided on PerkinElmer’s 3Q19 earnings call. We are not updating our prior guidance today
**Diagnostics Portfolio**

- **ImmunoDx**
  - 85% of revenue
  - 2019E revenue: $1.2B

- **Applied Genomics**
  - 15% of revenue

- **Reproductive Health**
  - #1 provider of biochemical prenatal testing & newborn screening
  - #2 in cord blood and tissue
  - #1 in global autoimmune IVD
  - #2 domestic diagnostics player in India
  - #1 platform agnostic automation provider to sequencing labs
  - #2 in microfluidic-based capillary electrophoresis

*Estimate is based on guidance provided on PerkinElmer’s 3Q19 earnings call. We are not updating our prior guidance today*
### Diagnostics Portfolio: Differentiated Capabilities

<table>
<thead>
<tr>
<th>KEY DIFFERENTIATORS</th>
<th>Reproductive Health</th>
<th>Immunodiagnostics</th>
<th>Applied Genomics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prenatal</td>
<td>Trusted global partner for NIPT, biochemical screening, and pre-eclampsia tests</td>
<td>Autoimmune</td>
<td>Liquid Handling</td>
</tr>
<tr>
<td>Newborn</td>
<td>Complete solution provider from high-quality, validated kits and consumables to instruments and software</td>
<td>Allergy</td>
<td>Automated Solutions</td>
</tr>
<tr>
<td>Genomics</td>
<td>Global services with ‘OMICS portfolio for leading rare disease capabilities underpinned by decades of expertise</td>
<td>Infectious Disease</td>
<td>NGS Library Prep</td>
</tr>
</tbody>
</table>

**Reproductive Health:**
- Trusted global partner for NIPT, biochemical screening, and pre-eclampsia tests.

**Immunodiagnostics:**
- Leader in autoimmune testing due to proprietary technology that enables the miniaturization and standardization of analysis.
- Dynamic capabilities that span from manual testing to semi- and fully-automated solutions.

**Applied Genomics:**
- Adaptable, scalable automated liquid handling solutions for high-throughput research laboratories.
- Integrated automated solutions which simplify microplate handling, liquid handling, and detection.
- Suite of reagents and sample prep supplies for a broad range of research and clinical applications … only automation player with extraction offering.
DISCOVERY & ANALYTICAL SOLUTIONS PORTFOLIO (DAS)

- #1 in pre-clinical imaging, detection and software for phenotypic & single-cell analysis
- #1 top-20 pharma services provider (OneSource)
- #1 in grain moisture and protein analysis and top-3 in dairy testing
- Top-3 provider of workflow solutions for Cannabis testing
- Provider of industry-leading platform, Nexion™ ICP-MS
- Complete portfolio across conventional contaminants and emerging seawater pollutants

60% Consumables, Services, Software
40% Instruments

$1.7B 2019E revenue*
DAS PORTFOLIO: DIFFERENTIATED CAPABILITIES

**DISCOVERY**
- Comprehensive portfolio of pre-clinical drug discovery instrumentation and screening reagents from fluorescence to luminescence and radiometrics

**ENTERPRISE**
- Broadest set of capabilities including asset management, lab performance analytics, and professional services

**INFOMATICS**
- Gold standard chemical communications software (ChemDraw); leading suite of electronic notebook and data visualization solutions (Signals & Spotfire)

**GRAIN & MILLING**
- Brodest portfolio for grain nutrition, functionality and safety testing

**DAIRY**
- Comprehensive range of testing applications for functionality and quality and for detection of pathogens, residues, and toxins

**CANNABIS & HEMP**
- Turn-key standard operating procedures (SOPs) with ability to drive full safety characterization

**CHEMICAL & ENERGY**
- Strong high-throughput lubricant analysis for wear metals, mining exploration, and production

**WATER & POLLUTANTS**
- Complete portfolio across conventional elemental & organic contaminants and seawater for emerging pollutants

**SEMICONDUCTOR & ELECTRONICS**
- Industry-leading speed, signal stability, and detection capabilities with Nexion™ ICP-MS platform
Leadership positions in attractive end markets

PerkinElmer End Market

- Diagnostics
- Life Sciences
- Food
- Applied

Market Growth (3 year CAGR)

- 6-8%
- 4-6%
- 4-6%
- 2-4%

Weighted Average Market Growth Rate
4-6%
Building on our STRATEGIC FOUNDATION to take our success to the NEXT LEVEL

- Attractive END MARKETS
- Improved PRODUCT MIX
- Increased GEOGRAPHIC REACH
- Strengthened CAPABILITIES
ALIGNED ORGANIZATION

UNIFIED GO-TO-MARKET

~5K global commercial resources

Driving complete PKI portfolio across end-markets

TRANSFORMATIVE INNOVATION

~1.5K person global R&D team

One team, fully leveraging cross-company capabilities

OPERATIONAL EXCELLENCE

Simplified processes to bring product, innovation, and talent closer to the customer

Attractive END MARKETS

Improved PRODUCT MIX

Increased GEOGRAPHIC REACH

Strengthened CAPABILITIES

STRATEGIC FOUNDATION

Driving complete PKI portfolio across end-markets ~5K global commercial resources

One team, fully leveraging cross-company capabilities ~1.5K person global R&D team

Simplified processes to bring product, innovation, and talent closer to the customer
UNIFIED GO-TO-MARKET

Bringing decision making closer to the customer

Empowered & accountable for agile decision making

Selling full breadth of portfolio tailored to workflow demands

4 focused end markets

Diagnostics

Life Sciences

Food

Applied

Costs to Serve

Customer Intimacy
TRANSFORMATIVE INNOVATION

Increasing technology convergence across end-markets

Aligned by leverageable technology verticals
(reagents, instruments, software, services)

Expanding assays, workflow solutions and data foundation on world-class instrumentation

R&D team

Positioned to drive

Unified global R&D

Product Vitality

Time to Market
OPERATIONAL EXCELLENCE

Advanced capabilities distributed globally …

AMERICAS
- Boston, MA
- Shelton, CT

EUROPE
- Groningen, Netherlands
- Machelen, Belgium

APAC
- Taicang, China
- Singapore

APPROXIMATELY 13,000 EMPLOYEES GLOBALLY

AMERICAS: 25% OF EMPLOYEES
EX. AMERICAS: 75% OF EMPLOYEES

Indicates major distribution centers
... with increasing product, innovation, and talent localized around the customer

APAC:

Taicang
>400 person mfg., innovation and distribution site with 
~25% in R&D roles

Shanghai
Increasing digital focus with a 
100 person informatics and 
software-focused R&D team

Singapore
Distribution center contributing to 20% improved cycle time since 2016

Indicates major distribution centers
Leveraging capabilities across the **ALIGNED ORGANIZATION**

**UNIFIED GO-TO-MARKET**

**TRANSFORMATIVE INNOVATION**

**OPERATIONAL EXCELLENCE**
ALIGNMENT IN ACTION: **CANNABIS SOLUTIONS**

**UNIFIED GO-TO-MARKET**

*Dedicated channel* with a differentiated approach to selling laboratory SOPs

**TRANSFORMATIVE INNOVATION**

*Seamlessly integrating* easy-to-use additions to the complete workflow

**OPERATIONAL EXCELLENCE**

*Pre-configured instruments* for reduced cycle times & high customer intimacy to provide feedback to R&D

---

**Sample-to-Solution Workflow Offering**

- **Sample Prep**
  - Liquid Handling
  - Contaminants
- **Safety**
  - Contaminants
- **Quality**
  - Compositional Analysis
- **Remote Monitoring**
  - Analytics

**Examples:**
- Liquid Handling
- Contaminants
- Compositional Analysis
- Analytics

**Select Near-term Workflow Additions**

- Integrated reagent kits for LC-MSMS assays on QSight
- Wholly connected workflow through Digital Solutions
ACCELERATING **OUTCOMES** for the betterment of people and environment through our **DIFFERENTIATED CAPABILITIES**

**ALIGNED ORGANIZATION**

- **UNIFIED GO-TO-MARKET**
- **TRANSFORMATIVE INNOVATION**
- **OPERATIONAL EXCELLENCE**

**STRATEGIC FOUNDATION**

- **Attractive** END MARKETS
- **Improved** PRODUCT MIX
- **Increased** GEOGRAPHIC REACH
- **Strengthened** CAPABILITIES
Advancing positive outcomes throughout a person’s life

- Carrier Screening, Pre-Implantation
- Maternal / Fetal Health
  - NIPT, Biochemical Screening, Pre-Eclampsia
- Newborn Health
  - Newborn Screening (Genetic & Biochemistry)
- Childhood
  - Rare Disease / Inherited Disease
- Family Planning
- Family Health
  - Allergy & Autoimmune, Infectious Disease

PerkinElmer
For the Better
Family health *begins with the mother* and the issues important to her

- **Highly accurate** genetic insights
- **Reduced health risks** for mother and child
- **Affordable options** w/o compromising precision
- Access to care with results they can trust
- Timely answers with reduced “no-call” rates
VANADIS™ NIPT: A Test for Every Woman

Precise results at an affordable price … enabling insights and comfort for every expectant mother regardless of risk profile

With Vanadis™ NIPT, PKI can serve as a single prenatal testing source

Vanadis™ NIPT & Biochemical Screening

Provides potential for additional content and applications

Vanadis™ NIPT’s cell-free DNA technology can be used to probe mutations from liquid biopsies for various clinical applications
Tests

Karyotype and chromosomal microarray

Findings & Initial Diagnosis

Normal 46, XX karyotype

Findings consistent with a clinical diagnosis of Kleefstra Syndrome

Presenting Patient

Five year old female

Clinical Presentation:

- Delayed motor and language development
- Hypertelorism
- Mild hypotonia

Prior Diagnosis:

Patient re-presented to the genetics clinic during early adolescence with additional complications not all consistent with Kleefstra: emotional outbursts, vertigo, neuropathic pain, and renal disease

Whole Genome Sequencing can identify all types of pathogenic variants in ONE test and provide dual diagnosis for actionable insight

New Diagnosis & Prognosis:

Pathogenic variant associated w/ FABRY DISEASE

To prevent renal failure, enzyme replacement therapy can be administered with effectiveness monitored by PKIG

Note: Representative case
Turning family health diagnoses from challenging into routine

Precise detection including emerging autoimmune diseases that are challenging to diagnose

Over 500 unique tests and 650+ allergens in portfolio

Examples:
- Zika
- Allergies
- Lupus
- Lyme
- Neuro
- Rheumatoid Arthritis

Presenting Patient
- New York Post reporter, 24 year old Susannah Cahalan
- Clinical presentation of violence to catatonia

Clinical Plight
- ~$1M worth of blood tests and brain scans that were inconclusive
- No clear treatment plan … psychiatric ward and potentially death

Correct Diagnosis
- Rare autoimmune disease (anti-NMDA receptor encephalitis)
- Antibody treatment for full recovery
Improving OUTCOMES through discovery and analysis of the factors that impact our health

- **Safer Food**
  - Broad-based Food Testing

- **Effective Therapies**
  - Drug Discovery & Personalized Medicine

- **Healthier Environment**
  - Air, Water, Soil, Microplastics Analysis

- **Smarter Research**
  - Disease & Translational Research
Supporting a **safer global food supply** as well as localized needs in China

**Consumer**
- **Limited confidence** in quality, safety and authenticity of their food
- **Refusing to buy local** until proven to be safe

**Government**
- Sweeping changes to consolidate & govern safety regulations
- Local players best positioned to respond

Fastest growing food safety testing market

10-12% 3-year CAGR

**Our portfolio has complete coverage across all:**

- **Customers**
  - Upstream
    - e.g. farmers
  - Mid-stream
    - e.g. processors
  - Downstream
    - e.g. retailers

- **End Markets**
  - Dairy
  - Grain & Milling
  - Rice
  - Seafood
  - Meat & Poultry

- **Technologies**
  - Broad-based Consumables
    - e.g. pathogen detection
  - Instruments
    - e.g. fit-for-purpose analyzers
  - Digital & Service
Preventing widespread health incidents through *rapid mycotoxin testing*

In recent years, China Mengniu Dairy Co., China’s largest dairy farm, reported milk contaminated with *Aflatoxin*, a substance that can cause severe liver damage & **liver cancer**

Cows had been **fed with grain** containing *Aflatoxin B1 / B2*

Today, there are considerably increased **gov’t enforced safety standards** for rapid mycotoxin testing

PKI is a **leading player in China for rapid mycotoxin testing of grains & seeds**

Mycotoxin testing extends across the entire food value chain expanding the addressable market across various stakeholders
Driving life changing and life saving drug discovery

Serving the complete workflow with genomic tools and automation and increasingly important phenotypic characterizations

Assays, Liquid Handling, Automation, Services and Informatics

- Target ID / Validation
- Lead Generation & Profiling
- Lead Optimization
- Pre-Clinical

Best-in-class high content imaging and informatics

Gene Therapy: launch of important discovery tools to advance new life saving therapies

AAV is one of the most actively investigated & manufactured vehicles for gene therapies with a growing need for precise particle characterization

Leading suite of imagers, analyzers, assays and informatics solutions analyzing phenotypic and sub-cellular components
eXXpedition is a non-profit organization that runs all-women sailing voyages across the world to investigate ocean plastic pollution causes and solutions.

PKI provided technology and service solutions focused on analyzing microplastics.

eXXpedition is leveraging PKI’s portable Spectrum Two that allows real-time analysis to identify polymer types and helps to explore solutions on dry land.

✓ Easy-to-use
✓ Powerful
✓ Compact
✓ Robust

PKI’s innovative technology provided eXXpedition with fast, accurate IR analysis that is ideal for use in remote-testing environments.
Differentiated Capabilities

Aligned Organization

Strategic Foundation

2019

✓

2020

Accelerating through outcomes across attractive end markets

Diagnostics

Life Sciences

Food

Applied
Long-term Vision

Accelerated outcomes through differentiation

Portfolio focus to where impact is greatest

Disproportionate growth in reagents, consumables, software, and services

Deep scientific capabilities driving agile innovation and customer intimacy

Passion with purpose, data-forward culture with talent localized around the customer
PerkinElmer is positioned for sustained above-market long-term growth.

Leadership positions in attractive end markets

- Diagnostics
- Life Sciences
- Food
- Applied

Weighted Average Market Growth Rate

4-6%

PerkinElmer is positioned for sustained above-market long-term growth.
PerkinElmer will host an
ANALYST DAY
in SEPTEMBER 2020 at the NYSE